Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00436) | |||||
---|---|---|---|---|---|
Name |
Miltefosine
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Miltefosine; 58066-85-6; Hexadecylphosphocholine; Miltex; Impavido; Hexadecylphosphorylcholine; n-Hexadecylphosphorylcholine; Miltefosinum; Miltefosina; hexadecyl 2-(trimethylammonio)ethyl phosphate; 1-Hexadecylphosphorylcholine; Miltefosin C; n-hexadecylphosphocholine; D-18506; miltefosin; C21H46NO4P; hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; UNII-53EY29W7EC; NSC605583; monohexadecylphosphocholine; hexadecyl (2-(trimethylAmmonio)ethyl) phosphate; CHEMBL125; monohexadecylphosphorylcholine; HePC;Hexadecyl phosphocholine; 53EY29W7EC; CHEBI:75283; MFCD00133396; MMV688990; NSC-605583; NCGC00095169-01; Miltefos; DSSTox_CID_25942; DSSTox_RID_81240; DSSTox_GSID_45942; Miltefosinum [INN-Latin]; Miltefosina [INN-Spanish]; Miltefosine [INN:BAN]; Fos-choline 16; Miltefosine (INN); CAS-58066-85-6; D 18506; Choline hexadecyl phosphate; BRN 3690495; Miltextrade mark; HePC Hydrate; Impavidotrade mark; D18506; Impavido (TN); Choline, inner salt; Miltefosine, 98%; TF-002; NSC 605583; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl Phosphorylcholine; H-1850; M-7200; SCHEMBL26215; 4-04-00-01460 (Beilstein Handbook Reference); SPECTRUM1505329; ETH098; DTXSID7045942; GTPL11355; Hexadecyl Phosphorylcholine Hydrate; HMS1922D16; HMS2089J15; HMS3649I09; Pharmakon1600-01505329; hexadecylphosphocholine, miltefosine; BCP04506; miltefosine (hexadecylphosphocholine); Tox21_111466; BDBM50034220; CCG-35584; CCG-36097; CCG-40025; DL-131; Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; NSC758968; 1-N-HEXADECYLPHOSPHORYLCHOLINE; AKOS015914886; Tox21_111466_1; BCP9000927; DB09031; NSC-758968; NCGC00095169-02; NCGC00095169-03; NCGC00095169-05; AK163678; HY-13685; BCP0726000071; FT-0608148; hexadecyloxy-2-trimethylammonioethylphosphorate; D02494; AB00642217-03; AB00642217_04; Miltefosine, >=98% (perchloric acid titration); A831718; Q411787; Hexadecyl 2-(Trimethylammonio)ethyl Phosphate Hydrate; 2-[hexadecoxy(hydroxy)phosphoryl]oxyethyl-trimethyl-ammonium; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester; [2-(Hexadecyloxy-hydroxy-phosphoryloxy)-ethyl]-trimethyl-ammonium; 3, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide; hexadecyl 2-(trimethyl-lambda~5~-azanyl)ethyl hydrogen phosphate; Phosphoric Acid Hexadecyl 2-(Trimethylammonio)ethyl Ester Hydrate; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Leishmaniasis | ICD-11: 1F54 | [1] | ||
PubChem CID | |||||
Formula |
C21H46NO4P
|
||||
Canonical SMILES |
CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
|
||||
InChI |
1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
|
||||
InChIKey |
PQLXHQMOHUQAKB-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3599"></iframe>
|
||||
3D MOL is unavailable | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 407.6 | Topological Polar Surface Area | 58.6 | |
XlogP | 6.7 | Complexity | 363 | ||
Heavy Atom Count | 27 | Rotatable Bond Count | 20 | ||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Miltefosine 50 mg capsule | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Magnesium stearate; Ferric oxide red; Talc; Titanium dioxide; Water; Silicon dioxide; Cellulose, microcrystalline; Gelatin
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Paladin Therapeutics | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Magnesium stearate; Ferric oxide red; Talc; Titanium dioxide; Water; Silicon dioxide; Gelatin, unspecified; Microcrystalline cellulose
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Profounda | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.